Abstract
Traumatic Brain Injury (TBI) is still the worldwide leading cause of mortality and morbidity in young adults. Improved safety measures and advances in critical care have increased chances of surviving a TBI, however, numerous secondary mechanisms contribute to the injury in the weeks and months that follow TBI. The past 4 decades of research have addressed many of the metabolic impairments sufficient to mitigate mortality, however, an enduring secondary mechanism, i.e. neuroinflammation, has been intractable to current therapy. Neuroinflammation is particularly difficult to target with pharmacological agents due to lack of specificity, the blood brain barrier, and an incomplete understanding of the protective and pathologic influences of inflammation in TBI. Recent insights into TBI pathophysiology have established microglial activation as a hallmark of all types of TBI. The inflammatory response to injury is necessary and beneficial while the death of activated microglial is not. This review presents new insights on the therapeutic and maladaptive features of the immune response after TBI with an emphasis on microglial polarization, followed by a discussion of potential targets for pharmacologic and non-pharmacologic treatments. In aggregate, this review presents a rationale for guiding TBI inflammation towards neural repair and regeneration rather than secondary injury and degeneration, which we posit could improve outcomes and reduce lifelong disease burden in TBI survivors.
Keywords: Traumatic brain injury, inflammation, microglia, pyroptosis, neuroprotection, post-traumatic stress disorder (PTSD).
CNS & Neurological Disorders - Drug Targets
Title:Targeting Microglial Polarization to Improve TBI Outcomes
Volume: 20 Issue: 3
Author(s): Matti Nathalie, Sai P. Polineni, Christopher N. Chin, Daniela Fawcett, Helene Clervius, Quesada S.L. Maria, Fernandez Legnay, Lucas Rego, Anil K. Mahavadi, Walter J. Jermakowicz, Lee SW-T, Shoji Yokobori and Shyam Gajavelli*
Affiliation:
- The Miami Project to Cure Paralysis, Department of Neurosurgery, University of Miami Miler School of Medicine, Miami, Florida, FL 33136,United States
Keywords: Traumatic brain injury, inflammation, microglia, pyroptosis, neuroprotection, post-traumatic stress disorder (PTSD).
Abstract: Traumatic Brain Injury (TBI) is still the worldwide leading cause of mortality and morbidity in young adults. Improved safety measures and advances in critical care have increased chances of surviving a TBI, however, numerous secondary mechanisms contribute to the injury in the weeks and months that follow TBI. The past 4 decades of research have addressed many of the metabolic impairments sufficient to mitigate mortality, however, an enduring secondary mechanism, i.e. neuroinflammation, has been intractable to current therapy. Neuroinflammation is particularly difficult to target with pharmacological agents due to lack of specificity, the blood brain barrier, and an incomplete understanding of the protective and pathologic influences of inflammation in TBI. Recent insights into TBI pathophysiology have established microglial activation as a hallmark of all types of TBI. The inflammatory response to injury is necessary and beneficial while the death of activated microglial is not. This review presents new insights on the therapeutic and maladaptive features of the immune response after TBI with an emphasis on microglial polarization, followed by a discussion of potential targets for pharmacologic and non-pharmacologic treatments. In aggregate, this review presents a rationale for guiding TBI inflammation towards neural repair and regeneration rather than secondary injury and degeneration, which we posit could improve outcomes and reduce lifelong disease burden in TBI survivors.
Export Options
About this article
Cite this article as:
Nathalie Matti , Polineni P. Sai, Chin N. Christopher , Fawcett Daniela , Clervius Helene , Maria S.L. Quesada , Legnay Fernandez, Rego Lucas , Mahavadi K. Anil , Jermakowicz J. Walter , SW-T Lee , Yokobori Shoji and Gajavelli Shyam *, Targeting Microglial Polarization to Improve TBI Outcomes, CNS & Neurological Disorders - Drug Targets 2021; 20 (3) . https://dx.doi.org/10.2174/1871527319666200918145903
DOI https://dx.doi.org/10.2174/1871527319666200918145903 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry New Developments of Clinical Trial in Immunotherapy for Alzheimer's Disease
Current Pharmaceutical Biotechnology Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Vascular Endothelium: Functioning in Norm, Changes in Atherosclerosis and Current Dietary Approaches to Improve Endothelial Function
Mini-Reviews in Medicinal Chemistry Neuropathic Pain: Is the End of Suffering Starting in the Gene Therapy?
Current Drug Targets Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Pharmacologic Strategies for Suppression of Lipid Peroxidation in Neurodegeneration
Current Neuropharmacology Raxofelast, (±)5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic Acid: A New Antioxidant to Modulate the Inflammatory Response During Ischemia-Reperfusion Injury and Impaired Wound Healing
Mini-Reviews in Medicinal Chemistry Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia
Current Alzheimer Research Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science Inhibition of Brain Ischemia-Caused Notch Activation in Microglia May Contribute to Isoflurane Postconditioning-Induced Neuroprotection in Male Rats
CNS & Neurological Disorders - Drug Targets Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Traumatic Brain Injury Altered Normal Brain Signaling Pathways: Implications for Novel Therapeutics Approaches
Current Neuropharmacology Advanced Neuroimaging Techniques in the Management of Glioblastoma Multiforme
Current Radiopharmaceuticals Cardiac Innervation and Sudden Cardiac Death
Current Cardiology Reviews Correlation of Alzheimer-like Tau Hyperphosphorylation and fMRI Bold Intensity
Current Alzheimer Research Dopaminergic Neuron-Like Cells Derived from Bone Marrow Mesenchymal Stem Cells by Lmx1α and Neurturin Overexpression for Autologous Cytotherapy in Hemiparkinsonian Rhesus Monkeys
Current Stem Cell Research & Therapy